GDF11/Myostatin and aging

Patel, Vishal; Demontis, Fabio

doi:10.18632/aging.100666

Cited by 25 publications

(24 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…On the other hand, new studies have undermined this hypothesis by indicating that GDF11 concentration in serum does not decrease with age but, conversely, increases . In addition to this debate, the tissue source of GDF11 found in circulating blood remains unknown . We hypothesized that GDF11 could be stored in circulating platelets and also that serum may contain higher concentrations than plasma as a result of sample manipulation errors.…”

Section: Introductionmentioning

confidence: 93%

Growth differentiation factor 11 (GDF11) – a promising anti‐ageing factor – is highly concentrated in platelets

et al. 2016

View full text Add to dashboard Cite

Recent research suggests that growth differentiation factor 11 (GDF11) could reverse age-related diseases and that its blood concentration decreases with age. This poses plasma from young donors as a therapeutic GDF11 source to treat age-related diseases. In addition, the tissue source of circulating GDF11 remains unknown. We analysed GDF11 levels in paired samples of serum, plasma and platelet lysate (PL) from 23 volunteers. Plasma and PL were collected by plateletpheresis. Here, we show that GDF11 is highly concentrated in platelets and that the circulating levels reported in previous studies could be biased as a result of serum sample manipulation.

show abstract

Section: Introductionmentioning

confidence: 93%

Growth differentiation factor 11 (GDF11) – a promising anti‐ageing factor – is highly concentrated in platelets

et al. 2016

View full text Add to dashboard Cite

show abstract

“…Emerging data indicate that the reversal of age-associated defects in stem cell stability and function could help to improve tissue maintenance and to prevent stem cell-derived carcinogenesis during aging (Patel & Demontis, 2014). Both stem cell-based interventions and other dietary and pharmacological interventions which induce stem cell-based regeneration and rejuvenation are likely to be very important for healthspan in the future, but are currently only beginning to be tested as modulators of lifespan in model organisms.…”

Section: Other Promising Potential Drugs and Drug Targetsmentioning

confidence: 99%

“…During aging, adult tissue stem cells exhibit impairments in functionality and exponential increases in premalignant mutations driven by cellintrinsic defects and alterations in the stem cell niche and the blood circulatory environment Behrens et al, 2014). Emerging data indicate that the reversal of age-associated defects in stem cell stability and function could help to improve tissue maintenance and to prevent stem cell-derived carcinogenesis during aging (Patel & Demontis, 2014). Both stem cell-based interventions and other dietary and pharmacological interventions which induce stem cell-based regeneration and rejuvenation are likely to be very important for healthspan in the future, but are currently only beginning to be tested as modulators of lifespan in model organisms.…”

Section: Stem Cellsmentioning

confidence: 99%

Interventions to Slow Aging in Humans: Are We Ready?

et al. 2015

View full text Add to dashboard Cite

The workshop entitled ‘Interventions to Slow Aging in Humans: Are We Ready?’ was held in Erice, Italy, on October 8–13, 2013, to bring together leading experts in the biology and genetics of aging and obtain a consensus related to the discovery and development of safe interventions to slow aging and increase healthy lifespan in humans. There was consensus that there is sufficient evidence that aging interventions will delay and prevent disease onset for many chronic conditions of adult and old age. Essential pathways have been identified, and behavioral, dietary, and pharmacologic approaches have emerged. Although many gene targets and drugs were discussed and there was not complete consensus about all interventions, the participants selected a subset of the most promising strategies that could be tested in humans for their effects on healthspan. These were: (i) dietary interventions mimicking chronic dietary restriction (periodic fasting mimicking diets, protein restriction, etc.); (ii) drugs that inhibit the growth hormone/IGF-I axis; (iii) drugs that inhibit the mTOR–S6K pathway; or (iv) drugs that activate AMPK or specific sirtuins. These choices were based in part on consistent evidence for the pro-longevity effects and ability of these interventions to prevent or delay multiple age-related diseases and improve healthspan in simple model organisms and rodents and their potential to be safe and effective in extending human healthspan. The authors of this manuscript were speakers and discussants invited to the workshop. The following summary highlights the major points addressed and the conclusions of the meeting.

show abstract

“…GDF11 shares much homology with myostatin, and myostatin is a negative regulator of muscle mass (McPherron 2010). Also the homologous gene myoglianin has been shown to preserve muscle function in fly aging models, together suggesting that GDF11 may preserve cardiac homeostasis and other tissues (Patel & Demontis 2014). …”

Section: Cardiac Aging Interventionsmentioning

confidence: 99%

Quality control systems in cardiac aging

Quarles

Dai

Tocchi

et al. 2015

Ageing Research Reviews

View full text Add to dashboard Cite

Cardiac aging is an intrinsic process that results in impaired cardiac function, along with cellular and molecular changes. These degenerative changes are intimately associated with quality control mechanisms. This review provides a general overview of the clinical and cellular changes which manifest in cardiac aging, and the quality control mechanisms involved in maintaining homeostasis and retarding aging. These mechanisms include autophagy, ubiquitin-mediated turnover, apoptosis, mitochondrial quality control and cardiac matrix homeostasis. Finally, we discuss aging interventions that have been observed to impact cardiac health outcomes. These include caloric restriction, rapamycin, resveratrol, GDF11, mitochondrial antioxidants and cardiolipin-targeted therapeutics. A greater understanding of the quality control mechanisms that promote cardiac homeostasis will help to understand the benefits of these interventions, and hopefully lead to further improved therapeutic modalities.

show abstract

GDF11/Myostatin and aging

Cited by 25 publications

References 9 publications

Growth differentiation factor 11 (GDF11) – a promising anti‐ageing factor – is highly concentrated in platelets

Growth differentiation factor 11 (GDF11) – a promising anti‐ageing factor – is highly concentrated in platelets

Interventions to Slow Aging in Humans: Are We Ready?

Quality control systems in cardiac aging

Contact Info

Product

Resources

About